health
BD - dedicated to improving people’s health
BD is a leading global medical technology company that develops,
manufactures and sells medical devices, instrument systems and reagents.
The Company is dedicated to improving people’s health throughout the
world. BD is focused on improving drug delivery, enhancing the quality
and speed of diagnosing infectious diseases and cancers, and advancing
research, discovery and production of new drugs and vaccines. BD’s
capabilities are instrumental in combating many of the world’s most
pressing diseases.
Director, Baurs Healthcare Mahanama Dodampegama, exchanging
agreement documents with Managing Director Becton Dickinson, Ram
Sharma. |
Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD
employs approximately 28,000 people in approximately 50 countries
throughout the world. The Company serves healthcare institutions, life
science researchers, clinical laboratories, the pharmaceutical industry
and the general public.
BD has a history of innovation in the medical devices and technology
area. In 1924, BD manufactured its first syringe made specifically for
insulin injection. In 1947, BD introduced the Vacutainer system,
improving the quality of blood samples by evacuating specimens directly
into tubes.
In 1950, the first sterile disposable blood collection set was
developed and sold to the American Red Cross. In 1952, BD provided
sterilisation expertise to NASA for the first Viking mission to Mars and
1973, BD - with Stanford University - manufactured its first FACS
instrument, pioneering the company’s involvement in cytology.
In Sri Lanka BD has been a regular supplier to SPC since 2004, for a
range of products including disposable syringes and spinal anaesthesia
needles. BD has been the recipient of the “merit award - best supplier
surgical category”, for the last three years in a row.
BD is known worldwide for the extensive training, education and value
added services to its customers. To provide the same to Sri Lankan
customers and to increase it presence in the growing private market, BD
has now positioned a senior manager here in Colombo itself.
Baur and Co. are the local agents for BD, and encouraged by the
support from BD. This will enable the company to better support their
existing and prospective customers through various initiatives like
training on clinical applications of flowcytometry eg. Leukemia and
Lymphoma, best-in-class programmes on injection and infusion safety,
blood collection and infections disease diagnosis. |